First Patient Treated Worldwide with Accuray's New TomoHDA™ System Advanced Radiation Treatment Now Available to Cancer Patients in France
SUNNYVALE, Calif., June 5, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today the first patient has been treated with its new TomoHDA™ System at Centre Oscar Lambret in Lille, France. Building upon the proven TomoTherapy® Hi-Art® and TomoHD™ technologies, the TomoHDA System is a fully-integrated radiation therapy system designed to treat the full spectrum of cancer patients. Performance enhancements, unrivaled dose distributions and faster treatments are among the multiple new benefits of the TomoHDA System. With the addition of this latest innovation in the TomoTherapy family, Centre Oscar Lambret will be capable of providing excellent care to more patients as a result of the TomoHDA System's increased speed when computing treatment plans and delivering radiation treatment.
"Last month we successfully treated a breast cancer patient with our new TomoHDA. When it comes to cancer care, we are selective in the investments we make and only choose treatments that we believe will make a difference in the quality of care we provide to patients," said Prof. Eric Lartigau, M.D., Ph.D., Centre Oscar Lambret. "We are equipping our clinicians with the new TomoHDA technology on top of our two existing TomoTherapy Systems and CyberKnife System, because we believe it is a true innovation that has the potential to optimize cancer care for the full spectrum of cancer patients we treat, especially those battling breast cancer."
Centre Oscar Lambret is a leader in radiation oncology treatment with three TomoTherapy Systems on-site and a CyberKnife System. All three TomoTherapy Systems are equipped with VoLO™ Technology, offering real-time efficiency for treatment planning and dose calculation. VoLO Technology relies on high-end graphics processing unit (GPU) hardware and software that leverage the GPU's parallel processing abilities to perform dose calculation and optimization in a matter of minutes even for the most complex cases.
"Accuray's significant enhancements to its TomoTherapy and CyberKnife radiation oncology systems have been well-received across Europe with centers in Germany and now France acquiring them in recent months," said Lionel Hadjadjeba, general manager for Europe, India, Middle East, Africa (EIMEA) and senior vice president of International Business at Accuray. "Accuray looks forward to working closely with these centers to ensure patients continue to receive the best possible care."
"Evidenced by Centre Oscar Lambret's adoption of three TomoTherapy Systems and a CyberKnife System, the center clearly recognizes the value Accuray's technologies bring to cancer care," said Joshua H. Levine, president and chief executive officer of Accuray. "Centre Oscar Lambret's decision to invest deeply in Accuray's radiation oncology treatment solutions helps cement its worldwide leadership in cancer treatment and national clinical programs and is in line with their ongoing missions toward care, research and academic teaching and training."
The new TomoHDA System is equipped with the VoLO Technology as well the TomoEDGE™ Dynamic Jaws technology making it the gold standard for image-guided IMRT (intensity-modulated radiation therapy) treatment, offering faster treatments. The new TomoEDGE technology allows for sharper dose sculpting and reduces treatment time for many patients by approximately half, which will enable clinics to treat more patients per day. Additionally through the use of 3D daily imaging of the tumor site throughout a patient's course of radiation treatment, physicians often use the information to make important changes to treatment plans ensuring optimal delivery of radiation to only the tumor site, sparing surrounding critical structures and healthy tissue.
About Centre Oscar Lambret
Centre Oscar Lambret cancer centre is the regional reference centre of the North French region. Its four oncology missions are care, research and academic teaching and training. The radiation therapy department is headed by Prof. Lartigau, M.D., Ph.D. and Director in charge of research, scientific cooperation and University relations. The radiation department treats 3,500 new patients every year. For more information on Centre Oscar Lambret, please visit http://www.centreoscarlambret.fr/.
Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that develops, manufactures and sells personalized, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The Company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, dose distributions, treatment times, clinical results, patient outcomes, and the Company's leadership position in radiation oncology innovation. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K filed on September 10, 2012, as updated in our Form 10-Qs filed on November 8, 2012, February 6, 2013, and May 9, 2013 and as updated periodically by our other filings. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.
SOURCE Accuray Incorporated